We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative ... Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others. Show more
NL 00-0000000 false 0001651311 0001651311 2024-03-05 2024-03-05 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K ...
– Gilead Receives Exclusive Option to License Novel Trispecific Therapeutics Resulting from the Collaboration – Gilead Sciences, Inc. (Nasdaq:GILD) and Merus N.V. (Nasdaq:MRUS) today announced a...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...
Table of Contents As filed with the Securities and Exchange Commission on February 28, 2024 Registration No. 333- UNITED STATES...
- Petosemtamab in 1L HNSCC in combination with pembrolizumab initial interim clinical data planned for 2Q24; preparing for a potential phase 3 trial - Petosemtamab in 2L+ HNSCC phase 3 trial...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.19 | -2.59033521985 | 45.94 | 47.5899 | 44 | 467701 | 45.83130576 | CS |
4 | -5.07 | -10.1766358892 | 49.82 | 52.035 | 43.39 | 666451 | 47.04953984 | CS |
12 | 16.89 | 60.6245513281 | 27.86 | 52.035 | 27.72 | 600502 | 41.41855445 | CS |
26 | 19.71 | 78.714057508 | 25.04 | 52.035 | 19.805 | 504026 | 33.45492776 | CS |
52 | 26.82 | 149.581706637 | 17.93 | 52.035 | 17.15 | 433106 | 28.70729315 | CS |
156 | 23.77 | 113.298379409 | 20.98 | 52.035 | 12.03 | 338623 | 25.19837967 | CS |
260 | 32.01 | 251.25588697 | 12.74 | 52.035 | 10.18 | 240730 | 23.86896963 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions